Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DOES AMINOPHYLLINE BENEFIT ADULTS ADMITTED TO THE HOSPITAL FOR AN ACUTE EXACERBATION OF ASTHMA
Autore:
HUANG D; OBRIEN RG; HARMAN E; AULL L; REENTS S; VISSER J; SHIEH G; HENDELES L;
Indirizzi:
UNIV FLORIDA,HLTH SCI CTR,BOX 100486 GAINESVILLE FL 32610 UNIV FLORIDA,HLTH SCI CTR,BOX 100486 GAINESVILLE FL 32610
Titolo Testata:
Annals of internal medicine
fascicolo: 12, volume: 119, anno: 1993,
pagine: 1155 - 1160
SICI:
0003-4819(1993)119:12<1155:DABAAT>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOSE-RESPONSE; THEOPHYLLINE; TOXICITY; THERAPY; MODELS;
Keywords:
AMINOPHYLLINE; ASTHMA; THERPHYLLINE; ALBUTEROL; METHYLPREDNISOLONE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
D. Huang et al., "DOES AMINOPHYLLINE BENEFIT ADULTS ADMITTED TO THE HOSPITAL FOR AN ACUTE EXACERBATION OF ASTHMA", Annals of internal medicine, 119(12), 1993, pp. 1155-1160

Abstract

Objective: To determine the effect of adding intravenous theophylline(administered as aminophylline) to nebulizations of albuterol and intravenous methylprednisolone in adults hospitalized for acute asthma. Design: Randomized, placebo-controlled, double-blind study. Setting: Inpatient service of a tertiary-care, university teaching hospital. Patients: 21 adults (22 to 48 years old)-10 in the aminophylline group and11 in the placebo group. Interventions: Nebulized albuterol, 2.5 or 5.0 mg every 0.5 to 4 hours; intravenous methylprednisolone, 60 mg every 6 hours; and either individualized doses of aminophylline or placebofor 48 hours. Measurements: Forced expiratory volume in 1 second (FEV1), the number of ''as needed'' albuterol nebulizations and total dose, asthma symptom scores, and adverse effects. Results: At admission from the emergency department, the mean +/- SD baseline FEV1 was 49% +/-19% of the predicted value in the aminophylline group and 43% +/- 13%of the predicted value in the placebo group. The improvement in FEV1 at 3 hours was greater in the aminophylline group (29% +/- 23% compared with 10% +/- 10% in the placebo group; mean difference, 19 percentage points; 95% CI, 3 to 35 percentage points; P = 0.023). At 48 hours, FEV1 was 75% +/- 19% of the predicted value in the aminophylline groupand 58% +/- 15% of the predicted value in the placebo group (mean difference, 17 percentage points; CI, 0.2 to 34.8 percentage points; P = 0.048). Aminophylline-treated patients required fewer nebulizations ofalbuterol (10.3 +/- 3.8 compared with 16.4 +/- 5.3; mean difference, -6.1; CI, -10.3 to -1.8) and less total dosage (34 +/- 16 mg compared with 70 +/- 34 mg; mean difference, -36 mg; CI, -60.6 to -11.3 mg P = 0.02). No statistical differences were observed in asthma symptom scores or frequency of adverse effects. Conclusions: Individualized doses of intravenous theophylline added to frequent nebulizations of albuterol and intravenous methylprednisolone appear to benefit adults admitted to the hospital with acute asthma and are well tolerated when serum concentrations are maintained in the therapeutic range.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 17:26:17